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Abstract:  12 
Background. Previous studies reported human papillomaviruses (HPVs) in middle ear tumors, 13 
whereas these viruses have been poorly investigated in chronic inflammatory middle ear diseases. 14 
The purpose of this study was to investigate HPVs in non-tumor middle ear diseases, including 15 
chronic otitis media (COM). Methods. COM specimens (n=52), including chronic suppurative otitis 16 
media (CSOM) (n=38) and cholesteatoma (COMC) (n=14), as well as normal middle ear specimens 17 
(NME) (n=56) were analyzed. HPV DNA sequences and DNA loads were analyzed by quantitative 18 
PCR. HPV genotyping was performed by direct sequencing of the amplimers. Results. HPV DNA 19 
was detected in 23% (12/52) of COM and in 30.4% (17/56) NME (p>0.05). Specifically, HPV DNA 20 
sequences were revealed in 26.3% (10/38) of CSOM and in 14.3% (2/14) COMC (p>.05). Interestingly, 21 
the HPV DNA load was higher in COMC (mean 7.47 copy/cell) than in CSOM (mean 1.02 copy/cell), 22 
and NME (mean 1.18 copy/cell) (P=.03 and P=.017 versus CSOM and NME, respectively). HPV16 23 
and HPV18 were the main genotypes detected in COMC, CSOM and NME. Conclusions. This data 24 
indicates that HPV-positive CSOM and COMC are generally associated with higher viral DNA 25 
loads as compared to NME. In addition, for the first time, HPVs were detected in normal middle 26 
ear mucosa specimens. This result suggests that NME is an additional epithelial tissue that can be 27 
HPV infected. 28 
Keywords: HPV; infection; viral DNA load; inflammation; middle ear; chronic otitis media 29 
 30 
1. Introduction 31 
HPV infection is often associated to benign diseases and malignant tumors affecting the upper 32 
respiratory tract, including respiratory papillomatosis and oropharyngeal cancers [1,2]. Several 33 
studies also reported the HPV involvement in the development of middle ear squamous cell 34 
carcinoma [3–9]. Few studies are currently available for HPV in non-tumor middle ear diseases, such 35 
as chronic otitis media (COM), including chronic suppurative otitis media (CSOM) and chronic otitis 36 
media with cholesteatoma (COMC) [3–10].  37 
CSOM is a middle ear disease relies on chronic inflammation. Different pro-38 
inflammatory cytokines, such as TNF-α, IL-1β, IFN-γ, IL-6, have been found to be up-regulated in 39 
the middle ear mucosa sampled from CSOM patients [11]. However, the etiology of CSOM remains 40 
to be determined. The relationship between HPV infection and inflammation has been previously 41 
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reported [12]. It has been shown that persistent infection of high risk HPVs leads to the increase of 42 
proinflammatory cytokines, including IL-6, TNF-α, and MIP-1α [13]. In addition, high-risk HPV type 43 
16 (HPV16) is able to increase the expression of cyclooxygenase- (COX-) 2, a key enzyme in the 44 
synthesis of prostaglandins, which are important mediators of inflammation [14,15]. Until now, only 45 
a single study reported HPV DNA sequences in CSOM, whereby different HPV genotypes, as HPV16, 46 
HPV18 and HPV6, have been detected in 30.7% of CSOM [4].  47 
COMC is a form of expanding growth consisting of keratinizing squamous cell epithelium [16]. 48 
There is a great interest into the etiopathogenesis of HPV-associated cholesteatoma because HPV 49 
commonly infects the stratified epithelium [17,18]. However, conflicting data have been reported for 50 
HPV in COMC [10,19–21]. HPV sequences have been detected in COMC at different prevalence, 51 
ranging from 3% to 70% [10,19–21]. Moreover, no specific HPV genotypes have been associated to 52 
COMC, as high- and low-risk HPVs, such as HPV16, HPV18 and HPV6 and HPV11, have been 53 
detected [10,19–21].  54 
One emerging evidence is that HPV infection can occur in different anatomical sites. Since HPV 55 
infects epithelia [22], all anatomical sites covered with epithelial tissues are potentially exposed to 56 
HPV infection. Apart from pluristratified tissues of cervix [23], vulva [24], and oral-pharynx [25], 57 
HPV sequences have been detected in simple epithelia from several anatomical districts, such as lung 58 
[26], upper respiratory tract [27], larynx [28] and nose [29]. Since the middle ear mucosa is composed 59 
of respiratory epithelium, and it is connected with the Eustachian tube to the oral and respiratory 60 
regions, HPV infection may also occur in the middle ear mucosa. However, previous studies have 61 
been mainly performed in COM and tumor samples, while no studies are currently available on the 62 
HPV infection in normal middle ear mucosa.   63 
Therefore, in this study, HPV sequences, viral DNA load and HPV genotypes were investigated 64 
in middle ear specimens from patients affected by COM, including CSOM and COMC, as well as in 65 
normal middle ear specimens (NME). 66 
 67 
2. Results 68 
2.1. HPV DNA detection  69 
HPV sequences were investigated by quantitative PCR (qPCR) in COM specimens (n=52), 70 
including CSOM (n=38) and COMC (n=14), as well as in NME specimens (n=56). Overall, HPV DNA 71 
was detected in 23% (12/52) of COM and 30.4% (17/56) NME specimens (p>.05; Figure 1). Specifically, 72 
26.3% (10/38) of CSOM and 14.3% (2/14) of COMC tested positive for HPV sequences (p>.05; Figure 73 
1).  74 
 75 
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Figure 1. Prevalence of HPV DNA in middle ear mucosa specimens. The presence of HPV DNA was 76 
investigated in chronic otitis media specimens (n=52) (COM), including chronic suppurative otitis 77 
media (n=38) (CSOM) and chronic otitis media with cholesteatoma (n=14) (COMC) as well as normal 78 
middle ear specimens (n=56) (NME). No statistically significant differences were observed within 79 
groups (P>0.05). 80 
 81 
2.2. HPV DNA load     82 
HPV DNA load from middle ear mucosa specimens was determined by qPCR (Figure 2, Table 83 
1). The mean of HPV DNA load was 2.09 copy/cell (range 0.01-8.67 copy/cell) in COM (n=12) and 1.18 84 
copy/cell (range 0.20-1.96 copy/cell) in NME (n=17) specimens (Figure 2).  85 
 86 























Figure 2. Mean HPV DNA load detected by qPCR analysis. The mean HPV DNA load (viral DNA 88 
copy/cell) was determined in HPV-positive chronic otitis media specimens (n=12) (COM), including 89 
chronic suppurative otitis media (n=10) (CSOM) and chronic otitis media with cholesteatoma (n=2) 90 
(COMC) as well as normal middle ear specimens (n=17) (NME). Error bars represent standard error 91 
of mean. *P<.05 versus CSOM and NME. 92 
 93 
Specifically, the mean HPV DNA load was 1.02 copy/cell (range 0.01-2.36 copy/cell) in CSOM 94 
(n=10) and 7.47 copy/cell (range 6.28-8.67 copy/cell) in COMC (n=2) specimens. The difference of the 95 
HPV DNA load between COMC and CSOM as well as between COMC and NME was statistically 96 
significant (P=.03 and P=.017 versus CSOM and NME, respectively, Table 1). Although the number 97 
of COMC was very limited in sample size (n=14), it was interesting to verify that the two HPV-98 
positive COMC samples carried a viral DNA load three- and four-fold higher than the highest viral 99 
DNA load detected in the HPV-positive CSOM and NME samples, respectively. 100 
  101 
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Table 1. Mean HPV DNA load in middle ear mucosa specimens revealed by qPCR analysis. 102 
 103 
COM: chronic otitis media; CSOM: chronic suppurative otitis media; COMC: chronic otitis media 104 
with cholesteatoma; NME: normal middle ear. † P=.030 versus CSOM; ‡P=.017 versus NME. 105 
 106 
2.3. HPV genotyping 107 
HPV genotypes were determined by direct sequencing analysis in HPV-positive (n=29) middle 108 
ear mucosa specimens. Twenty-nine qPCR products, from CSOM (n=10), COMC (n=2) and NME 109 
(n=17) were sequenced. DNA sequencing confirmed the presence of HPV in all specimens analyzed. 110 
HPV genotypes belonged to HPV16, HPV18, and HPV11. Specifically, HPV16 genotype was present 111 
in 100% (2/2) COMC, 50% (5/10) CSOM and 52% (9/17) NME, while HPV18 genotype was detected 112 
in 20% (2/10) CSOM and 23.5% (4/17) NME. HPV11 genotype was detected in 20% (2/10) and 5.9% 113 
(1/17) CSOM and NME, respectively. The simultaneous presence of HPV16 and HPV18 genotypes 114 
was detected in 10% (1/10) and 17.6% (3/17) CSOM and NME, respectively.  115 
 116 
2.4. Association between HPV and co-factors 117 
To evaluate the involvement of HPV co-factors in the etiopathogenesis of COM, a univariate 118 
analysis was performed between HPV-positive specimens and age, smoke and gender (Table 2). 119 
Results indicated that the HPV prevalence was higher in CSOM patients aged ≥65 yrs compared to 120 
age-matched NME and to CSOM patients aged ≤64 yrs (P=.006 and P=.020 versus NME and CSOM, 121 
respectively; Table 2). Moreover, HPV prevalence was higher in NME specimens from smokers than 122 
in NME from non-smokers (P=.037; Table 2). 123 
   124 
Table 2. Association between HPV and co-factors in CSOM, COMC and NME. 125 
 126 
Pathogens 2020, 9, x FOR PEER REVIEW 5 of 12 
 
CSOM: chronic suppurative otitis media; COMC: chronic otitis media with cholesteatoma; NME: 127 
normal middle ear; †P=.020 versus CSOM aged ≤64 yrs; ‡P=.006 versus NME aged ≥65 yrs; §P=.037 128 
versus NME no-smokers. 129 
3. Discussion 130 
In this study, HPV DNA sequences, viral DNA loads and genotypes were investigated in chronic 131 
otitis media (COM) specimens, including chronic suppurative otitis media (CSOM) and chronic otitis 132 
media with cholesteatoma (COMC), as well as in normal middle ear (NME) specimens. 133 
CSOM is a middle ear disease, which depends on chronic inflammation. The aetiology of CSOM 134 
is largely unknown. High- and low-risk HPV sequences in 30.7% of CSOM have been previously 135 
reported [4]. Similarly, in the present study, 26% CSOM specimens tested positive for HPV, including 136 
high-risk and low-risk HPV genotypes, i.e. HPV16, HPV18 and HPV11. As HPV prevalence, viral 137 
DNA load and genotypes were similar in CSOM and NME specimens, no association between HPV 138 
and CSOM was found. However, a significant higher HPV prevalence was detected in CSOM patients 139 
≥65 years old than in CSOM patients ≤65 years old, suggesting that HPV infection and old age may 140 
be co-factors in the etiopathogenesis of CSOM. One explanation is that HPV infection may persist 141 
longer in the middle ear mucosa of older than younger individuals, as shown for HPV infection in 142 
uterine cervix [30]. Considering the already known promoting role of the high-risk HPV infection in 143 
inflammation, our results suggest that the high-risk HPV infection may play a role in triggering 144 
inflammation of the middle ear mucosa in the elderly, ultimately leading to the development of 145 
CSOM. Thus, high-risk HPV infection of middle ear may explain, at least in part, in a subset of COM, 146 
the etiopathogenesis of CSOM. 147 
COMC is a disorder of the middle ear consisting of keratinizing squamous cell epithelium. 148 
Studies on HPV in COMC are widely different in prevalence rates, ranging from 3% to 70% [19,31,32], 149 
with some reporting detection of only low-risk HPVs, HPV6 and HPV11 [3,10], and others both low-150 
risk and high-risk HPVs, mainly HPV16 [3]. In our study, the HPV prevalence was 14% in COMC, 151 
and the high-risk HPV16 was the only genotype detected. Interestingly, the HPV16 DNA load was 152 
significantly higher in COMC (mean 7.47 copy/cell) compared to CSOM (mean 1.02 copy/cell) and 153 
NME (mean 1.18 copy/cell). This result may reflect the higher proliferation rate of HPV-infected cells 154 
from COMC compared to CSOM and NME, suggesting that viral DNA replication may occur in 155 
COMC. It has been reported that HPV infection leads to the expression of the viral oncoproteins E6 156 
and E7, which stimulate cell growth and viral DNA replication [22,33–37]. Although no studies are 157 
available on HPV DNA load in normal and pathological middle ear tissues, our results are in 158 
agreement with previous uterine cervix investigations reporting mean of viral DNA copy/cell from 159 
0.1 to 18 in cervical intraepithelial neoplasia and less than one viral DNA copy/cell in normal cervical 160 
tissues [37,38]. Thus, our data support and extend previous results confirming that HPV sequences 161 
can be detected in COMC. Moreover, the increased viral DNA load in COMC compared to CSOM 162 
and NME provides indirect evidence of an active infection, suggesting that HPV may play a role in 163 
the development of COMC.  164 
The role of the HPV infection in middle ear diseases onset remains to be elucidated. In this 165 
context, it should be recalled that some HPV-infected subjects, due to their genetic or immunological 166 
characteristics, are more prone/susceptible to the viral activity leading to diseases, as reported for the 167 
HPV-positive uterine cervix tissues [30]. It is possible that older patients, due to the immune 168 
senescence, do not react properly to HPV infection in the middle ear mucosa, thus favoring with the 169 
higher HPV DNA load the inflammation process and the disease onset/progression. 170 
Notably, it cannot be excluded that the presence of concomitant pathogenic agents, during HPV 171 
infection, could potentially increase the host susceptibility in developing inflammatory middle ear 172 
diseases. Indeed, a number of case–control studies reported an association between pathogenic 173 
infectious agents, such as Staphylococcus aureus [39,40] and Pseudomonas aeruginosa [41–43] with 174 
inflammatory middle ear diseases. Further studies based on the investigation of viral and bacterial 175 
co-infections may clarify this issue. 176 
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The difference in HPV DNA prevalence, among available studies, could be related to (i) 177 
differences in sampling, i.e. frozen storage, as in our study vs formalin fixed [10,19–21]; (ii) storage 178 
conditions, (iii) method sensitivity for HPV DNA isolation and PCR detection [10,19,20]. Further 179 
studies with a larger sample size including cancer tissues are needed to assess the role of the high-180 
risk HPV infection in COMC. 181 
In this study, for the first time, HPV sequences were detected in NME. Indeed, HPV sequences 182 
were found in 30% of NME, indicating that the middle ear mucosa is an additional epithelial tissue 183 
susceptible to the HPV infection. High-risk and low-risk HPV genotypes, i.e. HPV16, HPV18 and 184 
HPV11, were detected in the middle ear mucosa. This result is in agreement with previous studies, 185 
which reported HPV infection in several normal tissues [25,44]. Although middle ear epithelium is 186 
not considered the primary target tissue of HPV, factors such as inflammation and smoke can trigger 187 
the development of metaplastic tissue, which is the preferred target tissue of the viral infection. It is 188 
well recognized that metaplasia arises in the middle ear during acute and chronic events triggered 189 
by infection agents or smoke. Accordingly, in our study HPV sequences were found to be present at 190 
higher prevalence in NME specimens from smokers than in NME from non-smokers, indicating that 191 
smoke may favor HPV middle ear infection.  192 
4. Materials and Methods  193 
4.1. Patients and specimens 194 
Middle ear mucosa specimens were collected from patients (n=52) suffering of COM (mean age 195 
± standard deviation [SD], 47.6±16.2 yrs), including CSOM (n=38) (mean age ± [SD], 53.7 ± 18.8 yrs) 196 
and COMC (n=14) (mean age ± [SD], 41.3 ± 13.6 yrs). NME specimens (n=56) (mean age±[SD], 197 
44.2±19.4 yrs) were collected from patients undergoing ear surgery for cochlear implantation or 198 
stapedoplasty. Exclusion criteria were: no previous ear surgery. Middle ear mucosa specimens were 199 
collected during surgery, or by middle ear swab through a tympanic perforation with a micro-200 
otoscopy. The study was performed in accordance with the Declaration of Helsinki (2008). 201 
Institutional Review Board (IRB) approval was obtained from University Hospital of Ferrara Ethical 202 
Committee (Authorization n. 160986, December 12th, 2016). Informed written consents were obtained 203 
from patients. 204 
4.2. DNA isolation 205 
DNA was isolated according to standard procedures [45,46]. Briefly, tissue specimens were 206 
incubated overnight with 100 ng/µl of proteinase K at 56°C to allow tissue digestion [47]. DNA was 207 
isolated using a QIAmp DNA Blood and Tissue Extraction Kit (Qiagen, Milan, Italy) [48]. For control, 208 
DNAs were extracted together with a sample of salmon sperm DNA and a mock sample lacking 209 
DNA. After purification, DNA was quantified by spectrophotometric reading (NanoDrop 2000, 210 
Thermo Scientific). DNA suitability for PCR analysis was evaluated amplifying the β-globin gene [18]. 211 
DNA samples were then stored at -80ºC until the time of the analysis. 212 
4.3. Viral DNA load quantification 213 
HPV DNA load was quantified by quantitative PCR (qPCR) assay, using SYBR green, with the 214 
CFX96 Touch™ RT-PCR Detection System (Bio-Rad, Segrate, Milan, Italy). DNA samples were 215 
analyzed by qPCR for HPV DNA sequences using the universal primer pair GP5+/GP6+, as reported 216 
before [49]. Briefly, 50 ng of human genomic DNA were used in 10 μl qPCR reactions, including 2x 217 
of the SsoAdvanced Universal SYBR Green Supermix, Bio-Rad (Hercules, CA, USA) and 0.5 μM of 218 
each primer. PCR thermal conditions were: an initial step at 95ºC for 5 min and 40 cycles at 95ºC for 219 
15s and 60ºC for 30s [49]. Each qPCR experiment was carried out using the recombinant plasmid 220 
vector containing the complete HPV16 genome (NC_001526.4), used as positive control. A standard 221 
curve was employed using 10-fold dilutions, from 108 to 10 copies, of specific recombinant plasmid 222 
to calculate the viral DNA load [50]. Human β-globin gene was used to determine the human cell 223 
equivalents of each sample under qPCR analysis. HPV DNA load values were reported as viral copies 224 
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per human cell equivalents (copy/cell). Negative controls were the two samples used during the DNA 225 
extraction, i.e. salmon sperm DNA and mock samples, and two qPCR controls, including HPV free 226 
human DNA and a non-template control [51]. Samples were run in triplicate for each qPCR assay. 227 
Experiments were run three times by different operators.  228 
4.4. HPV genotyping 229 
HPV genotypes were determined by direct sequencing analysis in HPV-positive middle ear 230 
samples carrying at least 1 copy/cell of viral DNA. qPCR amplicons were purified using the QIAquick 231 
PCR Purification Kit (Qiagen) [52]. Purified qPCR amplicons were sequenced with automated 232 
ABIPrism 3730xl Genetic Analyser (Applied Biosystems) [53]. The resulting HPV DNA sequences 233 
were BLAST versus HPV DNA belonging to different viral strains present in the National Center for 234 
Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) [54].  235 
4.5. Statistical analysis 236 
The prevalence of HPV DNA in CSOM, COMC and NME specimens was evaluated by a two-237 
sided chi-square test. Viral DNA load values were analyzed with the D'Agostino-Pearson test and 238 
means were compared with the non-parametric Kolmogorov e Smirnov test. Univariate analysis was 239 
employed to compare the features of CSOM, COMC and NME patients, such as age, gender and 240 
smoke, in association with HPV. Statistical analyses were performed using Graph Pad Prism version 241 
5.0 for Windows (Graph Pad, La Jolla, CA, USA) [55,56]. P-values <.05 were considered statistically 242 
significant [57].  243 
 244 
5. Conclusions 245 
In conclusion, this study shows that HPV sequences are present in CSOM, COMC and normal 246 
middle ear specimens. We also show that the high risk HPV16 and HPV18 are the main genotypes 247 
detected in CSOM, COMC and NME specimens. Lastly, although HPVs have been detected in CSOM, 248 
COMC and NME with similar prevalence, high risk HPV DNA load was higher in COMC compared 249 
to CSOM and NME. Altogether these data indicate that CSOM and COMC epithelia and normal 250 
middle ear mucosa are target tissues of HPV infection. It remains to be assessed whether the higher 251 
HPV DNA load detected in COMC is significant for a putative pathogenic role of HPV in this middle 252 
ear disease. 253 
 254 
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